Croissy-Beaubourg, April 23, 2013 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for its proprietary anti-CCP in vitro diagnostic (IVD) kit in rheumatoid arthritis. This test further expands the Fidis portfolio of diagnostic tests for auto-immunes diseases, which significantly decreases costs and time of analysis thanks to the Multiplex technology. Fidis is the most complete multiplex range of diagnostics currently marketed.
This new way of detecting anti cyclic citrullinated peptides (anti-CCPs) antibodies allows for highly-reliable detection of severe forms of RA through a more rapid dosing and at a lower cost than existing tests.
“This new CE mark shows our ability to further expand our high-value IVD portfolio. With this new addition to the Fidis range, we position ourselves as testing and monitoring leaders in auto-immune and inflammatory diseases. This anti-CCP test strengthens our in house products portfolio, in line with our development strategy. The new kits will be available internationally, like all our other Fidis products” commented Michel Finance, CEO of Theradiag.
The new anti-CCP test is the third proprietary diagnostic kit of Theradiag to obtain a CE mark this year. The auto-immune diseases segment grew strongly in 2012 (+17% for Fidis products), making-up for 43 percent of company sales in 2012.
Backed by its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has some 50 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
Tél: 01 64 62 10 12
and investor relations
Valentine Brouchot /
Tél. : 01 44 71 98 52
Tél. : 06 64 18 99 59
Tél. : 01 42 68 86 41